In vivo anti-tumor effect of PARP inhibition in IDH1/2 mutant MDS/AML resistant to targeted inhibitors of mutant IDH1/2-Reference-Cited by-同舟云学术

In vivo anti-tumor effect of PARP inhibition in IDH1/2 mutant MDS/AML resistant to targeted inhibitors of mutant IDH1/2

Published:2022-03-10 Issue:5 Volume:36 Page:1313-1323
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Gbyli Rana^ORCID,Song Yuanbin^ORCID,Liu Wei,Gao Yimeng^ORCID,Biancon Giulia,Chandhok Namrata S.,Wang Xiaman,Fu Xiaoying,Patel Amisha,Sundaram Ranjini,Tebaldi Toma^ORCID,Mamillapalli Padmavathi,Zeidan Amer M.,Flavell Richard A.^ORCID,Prebet Thomas^ORCID,Bindra Ranjit S.,Halene Stephanie^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

https://www.nature.com/articles/s41375-022-01536-x.pdf

Reference47 articles.

1. Showalter MR, Hatakeyama J, Cajka T, VanderVorst K, Carraway KL, Fiehn O, et al. Replication study: the common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Elife. 2017;6:e26030.

2. Winer ES, Stone RM. Novel therapy in Acute myeloid leukemia (AML): moving toward targeted approaches. Ther Adv Hematol. 2019;10:2040620719860645.

3. Clark O, Yen K, Mellinghoff IK. Molecular pathways: isocitrate dehydrogenase mutations in cancer. Clin Cancer Res. 2016;22:1837–42.

4. DiNardo CD, Jabbour E, Ravandi F, Takahashi K, Daver N, Routbort M, et al. IDH1 and IDH2 mutations in myelodysplastic syndromes and role in disease progression. Leukemia. 2016;30:980–4.

5. Losman JA, Kaelin WG Jr. What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer. Genes Dev. 2013;27:836–52.

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Star wars against leukemia: attacking the clones;Leukemia;2024-09-02

2. Therapeutic targeting of PARP with immunotherapy in acute myeloid leukemia;Frontiers in Pharmacology;2024-08-08

3. IDH1 regulates human erythropoiesis by eliciting chromatin state reprogramming in a metabolic enzyme independent manner;2024-08-05

4. IDH1 regulates human erythropoiesis by eliciting chromatin state reprogramming in a metabolic enzyme independent manner;2024-08-05

5. Clinical Implications of Isocitrate Dehydrogenase Mutations and Targeted Treatment of Acute Myeloid Leukemia with Mutant Isocitrate Dehydrogenase Inhibitors—Recent Advances, Challenges and Future Prospects;International Journal of Molecular Sciences;2024-07-19